RU2742247C2 - Однодоменные антитела, направленные против внутриклеточных антигенов - Google Patents

Однодоменные антитела, направленные против внутриклеточных антигенов Download PDF

Info

Publication number
RU2742247C2
RU2742247C2 RU2019126152A RU2019126152A RU2742247C2 RU 2742247 C2 RU2742247 C2 RU 2742247C2 RU 2019126152 A RU2019126152 A RU 2019126152A RU 2019126152 A RU2019126152 A RU 2019126152A RU 2742247 C2 RU2742247 C2 RU 2742247C2
Authority
RU
Russia
Prior art keywords
administration
sdab
seq
use according
ebola
Prior art date
Application number
RU2019126152A
Other languages
English (en)
Russian (ru)
Other versions
RU2019126152A (ru
RU2019126152A3 (https=
Inventor
Сунанда СИНГХ
Original Assignee
Сингх Биотекнолоджи, Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сингх Биотекнолоджи, Ллк filed Critical Сингх Биотекнолоджи, Ллк
Publication of RU2019126152A publication Critical patent/RU2019126152A/ru
Publication of RU2019126152A3 publication Critical patent/RU2019126152A3/ru
Application granted granted Critical
Publication of RU2742247C2 publication Critical patent/RU2742247C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11031—Arachidonate 12-lipoxygenase (1.13.11.31), i.e. lipoxygenase-type-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
RU2019126152A 2015-11-02 2016-11-02 Однодоменные антитела, направленные против внутриклеточных антигенов RU2742247C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562249868P 2015-11-02 2015-11-02
US62/249,868 2015-11-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2018120245A Division RU2741110C2 (ru) 2015-11-02 2016-11-02 Однодоменные антитела, направленные против внутриклеточных антигенов

Publications (3)

Publication Number Publication Date
RU2019126152A RU2019126152A (ru) 2019-12-04
RU2019126152A3 RU2019126152A3 (https=) 2020-05-13
RU2742247C2 true RU2742247C2 (ru) 2021-02-04

Family

ID=58634379

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2019126152A RU2742247C2 (ru) 2015-11-02 2016-11-02 Однодоменные антитела, направленные против внутриклеточных антигенов
RU2019126220A RU2742248C2 (ru) 2015-11-02 2016-11-02 Однодоменные антитела, направленные против внутриклеточных антигенов
RU2018120245A RU2741110C2 (ru) 2015-11-02 2016-11-02 Однодоменные антитела, направленные против внутриклеточных антигенов

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2019126220A RU2742248C2 (ru) 2015-11-02 2016-11-02 Однодоменные антитела, направленные против внутриклеточных антигенов
RU2018120245A RU2741110C2 (ru) 2015-11-02 2016-11-02 Однодоменные антитела, направленные против внутриклеточных антигенов

Country Status (14)

Country Link
US (4) US10369223B2 (https=)
EP (1) EP3371215A4 (https=)
JP (2) JP6918005B2 (https=)
KR (1) KR20180069064A (https=)
CN (2) CN108350064B (https=)
AR (1) AR106556A1 (https=)
AU (1) AU2016349876B2 (https=)
BR (1) BR112018008840B1 (https=)
CA (1) CA3002239A1 (https=)
IL (1) IL258742B (https=)
MX (1) MX2018005154A (https=)
RU (3) RU2742247C2 (https=)
TW (1) TWI746473B (https=)
WO (1) WO2017079314A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
CN113557246B (zh) * 2019-07-24 2023-09-01 韩国基础科学支援研究院 靶向αvβ3整联蛋白的单域抗体
CN111234019B (zh) * 2020-01-16 2022-06-24 佛山汉腾生物科技有限公司 抗ctla-4纳米抗体、药物组合物及其应用
CN111184864B (zh) * 2020-01-20 2022-01-14 武汉大学 Alox12特异性抑制剂在制备治疗非酒精性脂肪肝病和/或ⅱ型糖尿病的药物中的应用
CN113214392B (zh) * 2020-12-30 2022-07-01 中国人民解放军海军军医大学 抗水母毒素纳米抗体ky031、制备方法及用途
CN115414482A (zh) * 2022-07-13 2022-12-02 同济大学 Stat3信号通路抑制剂的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016183A1 (en) * 1999-08-30 2001-03-08 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
RU2186106C1 (ru) * 2001-03-29 2002-07-27 Вирусологический центр Научно-исследовательского института микробиологии Штамм гибридных клеток э4/n-6g5 животных mus musculus l., продуцирующих моноклональные антитела к вирусу эбола
CN104829710A (zh) * 2015-03-26 2015-08-12 中国人民解放军军事医学科学院微生物流行病研究所 一种抗埃博拉病毒的免疫球蛋白F(ab′)2及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
WO1991005066A1 (en) * 1989-10-05 1991-04-18 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Monoclonal antibodies to segments of hiv-1 reverse transcriptase
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
US5645836A (en) * 1995-04-14 1997-07-08 Research Development Foundation Anti-AIDS immunotoxins
AU6234700A (en) 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
CN1184484C (zh) 1999-12-20 2005-01-12 恩益禧电子股份有限公司 用来精确测量阻抗的装置及方法
DE10019157A1 (de) 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US20040052762A1 (en) 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof
JP2002253239A (ja) * 2001-02-27 2002-09-10 Jo Chiba ヒト免疫不全ウイルスの逆転写酵素の活性を阻害するポリペプチドをコードする遺伝子およびその利用
EP1433793A4 (en) * 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
WO2003055527A2 (en) * 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
AU2003219277A1 (en) 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
AU2003222171A1 (en) * 2002-04-05 2003-10-27 Selective Genetics, Inc. Compositions and methods for portal specific gene delivery and treatment of infection
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
RU2455312C2 (ru) * 2002-11-08 2012-07-10 Аблинкс Н.В. Однодоменные антитела, направленные против фактора некроза опухолей альфа, и их применение
WO2004041867A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
JP2004315394A (ja) * 2003-04-14 2004-11-11 Japan Science & Technology Agency レストンエボラウイルスに対するモノクローナル抗体及びこれを用いたレストンエボラウイルスの検出方法
US7368249B2 (en) * 2003-07-24 2008-05-06 The Curators Of The University Of Missouri Methods and compositions for evaluation and modulation of fertility
WO2005052002A2 (en) 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
FR2874017B1 (fr) * 2004-08-06 2006-11-24 Bio Rad Pasteur Sa Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih
US20060147997A1 (en) * 2004-11-30 2006-07-06 Virosys Pharmaceuticals, Inc. PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2008070363A2 (en) 2006-10-31 2008-06-12 Domantis Limited Intrabodies
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
KR20090001043A (ko) * 2007-06-29 2009-01-08 주식회사 에스엔피 제네틱스 Ａｌｏｘ１２ 및 ａｌｏｘ１５ 다형성과 아스피린 유도성천식과의 연관성
EP2008666A1 (en) 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
KR20090001043U (ko) 2007-07-26 2009-02-02 김기인 공간 보호 책상
WO2009033091A1 (en) 2007-09-06 2009-03-12 City Of Hope Treatment of th17-mediated autoimmune disease via inhibition of stat3
AU2008298560A1 (en) * 2007-09-14 2009-03-19 Ventana Medical Systems, Inc. Prostate cancer biomarkers
ES2447844T3 (es) * 2008-04-03 2014-03-13 Vib Vzw Anticuerpos de dominio individual capaces de modular la actividad BACE1
WO2009150539A2 (en) * 2008-06-10 2009-12-17 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against androctonus autralis hector toxins
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011163423A2 (en) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
DK2723769T4 (da) * 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
LT2908912T (lt) * 2012-10-18 2020-09-25 The Rockefeller University Plačiai neutralizuojantys anti-živ antikūnai
CN111437395A (zh) 2013-08-29 2020-07-24 希望之城 细胞穿透缀合物及其使用方法
EP2873679A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof
EP2873680A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
EP2899208A1 (en) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
KR102207381B1 (ko) 2014-10-23 2021-01-27 싱 몰레큘러 메디신, 엘엘씨 세포내 항원에 대해 지향된 단일 도메인 항체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016183A1 (en) * 1999-08-30 2001-03-08 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
RU2186106C1 (ru) * 2001-03-29 2002-07-27 Вирусологический центр Научно-исследовательского института микробиологии Штамм гибридных клеток э4/n-6g5 животных mus musculus l., продуцирующих моноклональные антитела к вирусу эбола
CN104829710A (zh) * 2015-03-26 2015-08-12 中国人民解放军军事医学科学院微生物流行病研究所 一种抗埃博拉病毒的免疫球蛋白F(ab′)2及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JEFFREY E. LEE et al., Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a Vλx-light chain, J Mol Biol., 2008, Vol.375, N.1, pp. 202-216. *
XIANGGUO QIU et al., Antibody therapy for Ebola Is the tide turning around?, Hum Vaccin Immunother, 2014, Vol.10, N.4, pp. 964-967 (см.в частности, ). *
XIANGGUO QIU et al., Antibody therapy for Ebola Is the tide turning around?, Hum Vaccin Immunother, 2014, Vol.10, N.4, pp. 964-967 (см.в частности, реферат). JEFFREY E. LEE et al., Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a Vλx-light chain, J Mol Biol., 2008, Vol.375, N.1, pp. 202-216. *

Also Published As

Publication number Publication date
JP7186266B2 (ja) 2022-12-08
CN108350064B (zh) 2021-08-10
RU2018120245A3 (https=) 2020-05-13
AU2016349876A1 (en) 2018-04-26
EP3371215A2 (en) 2018-09-12
RU2019126152A (ru) 2019-12-04
US20190314503A1 (en) 2019-10-17
MX2018005154A (es) 2018-08-15
BR112018008840A2 (pt) 2018-11-06
CA3002239A1 (en) 2017-05-11
WO2017079314A3 (en) 2017-06-22
CN108350064A (zh) 2018-07-31
RU2019126152A3 (https=) 2020-05-13
RU2018120245A (ru) 2019-12-02
TWI746473B (zh) 2021-11-21
US20170121395A1 (en) 2017-05-04
KR20180069064A (ko) 2018-06-22
IL258742A (en) 2018-06-28
JP6918005B2 (ja) 2021-08-11
RU2019126220A (ru) 2019-09-27
AU2016349876B2 (en) 2023-07-06
RU2742248C2 (ru) 2021-02-04
US10369223B2 (en) 2019-08-06
TW201716434A (zh) 2017-05-16
JP2021181450A (ja) 2021-11-25
WO2017079314A2 (en) 2017-05-11
IL258742B (en) 2022-05-01
US20220089783A1 (en) 2022-03-24
US11214626B2 (en) 2022-01-04
AR106556A1 (es) 2018-01-24
BR112018008840B1 (pt) 2020-11-10
US10195277B2 (en) 2019-02-05
EP3371215A4 (en) 2019-10-02
CN113512112A (zh) 2021-10-19
US20170121392A1 (en) 2017-05-04
RU2019126220A3 (https=) 2020-03-17
JP2019504107A (ja) 2019-02-14
BR112018008840A8 (pt) 2019-02-26
RU2741110C2 (ru) 2021-01-22

Similar Documents

Publication Publication Date Title
JP7186266B2 (ja) 細胞内抗原に対して向けられた単一ドメイン抗体
US9546211B2 (en) Single domain antibodies directed against TNF-alpha
AU2018274932B2 (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
CN114025785B (zh) 慢性炎症和病毒感染的诊断和治疗
US20220073596A1 (en) Method for the treatment of idiopathic pulmonary fibrosis
TW201345921A (zh) 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途
WO2016002820A1 (ja) 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
KR102822827B1 (ko) 칸디다에 대한 항체 및 이의 용도
WO2019011167A1 (zh) 双特异性重组蛋白
JP2024534833A (ja) 治療用単一ドメイン抗体
US20240043562A1 (en) Musk activation
RU2810002C2 (ru) Однодоменные антитела, направленные против внутриклеточных антигенов
WO2024020582A1 (en) Therapeutic neutralizing antibodies for sars-cov-2
TW201400501A (zh) 新穎抗體及其用途